BioSpace News Archive

New Research Describes Novel Base Editors with Enhanced Editing Efficiency, Specificity, and Targeting Range

Eli Lilly Canada announced that Health Canada approved TALTZ® on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis, which is also known as radiographic axial spondyloarthritis, who have responded inadequately to, or are intolerant to, conventional therapy.

LHC Group, Inc. announced details for the release of its results for the fourth quarter and year ended December 31, 2019.

Resonetics announced today that it has begun improvements on a new 37,000 square foot facility in San Diego. The building is undergoing a complete renovation to meet Resonetics’ requirements.

P4 Diagnostix, a network of nationally-recognized diagnostic testing laboratories, today announced the acquisition of the assets of Strand Diagnostics, creator of the know error® system.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to ION373 for the treatment of people with Alexander disease, a severe, progressive and debilitating condition that can eventually result in death due to loss of control over autonomic functions like breathing

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), today announced positive topline results from two pivotal Phase 3 clinical trials for an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company’s patented Multiplexed Molecular Penetration Enhancer (“MMPE™") technology.

Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,588,235 additional shares of common stock, at a public offering price of $17.00 per share.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC).

ArTara Therapeutics, Inc. (Nasdaq: TARA) (“ArTara” or the “Company”), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the appointment of Mr. Blaine Davis as chief financial officer effective February 11, 2020.